DK1272195T3 - Anvendelse af fulvestrant til behandling af resistent brystcancer - Google Patents
Anvendelse af fulvestrant til behandling af resistent brystcancerInfo
- Publication number
- DK1272195T3 DK1272195T3 DK01917289T DK01917289T DK1272195T3 DK 1272195 T3 DK1272195 T3 DK 1272195T3 DK 01917289 T DK01917289 T DK 01917289T DK 01917289 T DK01917289 T DK 01917289T DK 1272195 T3 DK1272195 T3 DK 1272195T3
- Authority
- DK
- Denmark
- Prior art keywords
- fulvestrant
- treatment
- breast cancer
- resistant breast
- resistant
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title abstract 2
- 208000026310 Breast neoplasm Diseases 0.000 title abstract 2
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 title abstract 2
- 229960002258 fulvestrant Drugs 0.000 title abstract 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 abstract 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 abstract 2
- 229940122815 Aromatase inhibitor Drugs 0.000 abstract 1
- 239000003886 aromatase inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0008172.9A GB0008172D0 (en) | 2000-04-05 | 2000-04-05 | Therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1272195T3 true DK1272195T3 (da) | 2006-01-16 |
Family
ID=9889101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK01917289T DK1272195T3 (da) | 2000-04-05 | 2001-04-02 | Anvendelse af fulvestrant til behandling af resistent brystcancer |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US20030158166A1 (OSRAM) |
| EP (2) | EP1272195B1 (OSRAM) |
| JP (1) | JP2003528919A (OSRAM) |
| KR (1) | KR100757764B1 (OSRAM) |
| CN (1) | CN1431905A (OSRAM) |
| AT (1) | ATE306270T1 (OSRAM) |
| AU (2) | AU4437201A (OSRAM) |
| BR (1) | BR0109789A (OSRAM) |
| CA (1) | CA2403608A1 (OSRAM) |
| CH (1) | CH1272195H1 (OSRAM) |
| CZ (1) | CZ303096B6 (OSRAM) |
| DE (1) | DE60113975T2 (OSRAM) |
| DK (1) | DK1272195T3 (OSRAM) |
| EE (1) | EE05026B1 (OSRAM) |
| ES (1) | ES2248300T3 (OSRAM) |
| GB (1) | GB0008172D0 (OSRAM) |
| HU (1) | HU230064B1 (OSRAM) |
| IL (2) | IL151932A0 (OSRAM) |
| IS (1) | IS2869B (OSRAM) |
| MX (1) | MXPA02009744A (OSRAM) |
| NO (1) | NO329949B1 (OSRAM) |
| NZ (1) | NZ539603A (OSRAM) |
| PL (1) | PL201175B1 (OSRAM) |
| RU (1) | RU2265438C2 (OSRAM) |
| SK (1) | SK287779B6 (OSRAM) |
| UA (1) | UA80388C2 (OSRAM) |
| WO (1) | WO2001074366A1 (OSRAM) |
| ZA (1) | ZA200207538B (OSRAM) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0116620D0 (en) * | 2001-07-07 | 2001-08-29 | Astrazeneca Ab | Formulation |
| IL159576A0 (en) * | 2001-07-07 | 2004-06-01 | Astrazeneca Ab | Pharmaceutical formulation for the intramuscular administration of fulvestrant |
| EP1623713A1 (en) * | 2004-07-09 | 2006-02-08 | Proskelia SAS | Cominations of pure anti-estrogen with aromatase inhibitors |
| US8557863B2 (en) * | 2005-09-27 | 2013-10-15 | Robert Benson Aylor | Suppression and prevention of tumors |
| CA2628747C (en) * | 2005-11-22 | 2014-01-21 | Incyte Corporation | Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer |
| US7910108B2 (en) * | 2006-06-05 | 2011-03-22 | Incyte Corporation | Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases |
| CA2835203A1 (en) * | 2011-05-09 | 2012-11-15 | University Of Virginia Patent Foundation | Compositions and methods for treating cancer |
| US9029582B2 (en) | 2011-05-20 | 2015-05-12 | Capital, Business Y Gestion De Finanzas S.L. | Pharmaceutical composition |
| US20160375234A1 (en) * | 2014-01-10 | 2016-12-29 | Atossa Genetic Inc. | Transpapillary methods and compositions for diagnosing and treating breast conditions |
| US9421264B2 (en) * | 2014-03-28 | 2016-08-23 | Duke University | Method of treating cancer using selective estrogen receptor modulators |
| CN116832020A (zh) | 2017-09-11 | 2023-10-03 | 阿托萨治疗学公司 | 制备和使用内昔芬的方法 |
| US20210253626A1 (en) * | 2018-05-24 | 2021-08-19 | Kashiv Biosciences, Llc | Prodrugs of fulvestrant |
| JP7662204B2 (ja) | 2019-07-03 | 2025-04-15 | アトッサ・セラピューティクス・インコーポレイテッド | エンドキシフェンの徐放性組成物 |
| CA3210276A1 (en) * | 2020-02-29 | 2021-09-02 | Frances E. Carr | Use of thyromimetics for the treatment of cancer |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541669B1 (en) * | 1998-06-08 | 2003-04-01 | Theravance, Inc. | β2-adrenergic receptor agonists |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
-
2000
- 2000-04-05 GB GBGB0008172.9A patent/GB0008172D0/en not_active Ceased
-
2001
- 2001-02-04 UA UA2002118734A patent/UA80388C2/uk unknown
- 2001-04-02 IL IL15193201A patent/IL151932A0/xx active IP Right Grant
- 2001-04-02 RU RU2002129355/14A patent/RU2265438C2/ru active
- 2001-04-02 EE EEP200200574A patent/EE05026B1/xx unknown
- 2001-04-02 WO PCT/GB2001/001500 patent/WO2001074366A1/en not_active Ceased
- 2001-04-02 CZ CZ20023309A patent/CZ303096B6/cs not_active IP Right Cessation
- 2001-04-02 AU AU4437201A patent/AU4437201A/xx active Pending
- 2001-04-02 MX MXPA02009744A patent/MXPA02009744A/es active IP Right Grant
- 2001-04-02 US US10/240,656 patent/US20030158166A1/en not_active Abandoned
- 2001-04-02 HU HU0300339A patent/HU230064B1/hu unknown
- 2001-04-02 AU AU2001244372A patent/AU2001244372B2/en not_active Expired
- 2001-04-02 EP EP01917289A patent/EP1272195B1/en not_active Expired - Lifetime
- 2001-04-02 KR KR1020027013366A patent/KR100757764B1/ko not_active Expired - Lifetime
- 2001-04-02 PL PL357936A patent/PL201175B1/pl unknown
- 2001-04-02 JP JP2001572110A patent/JP2003528919A/ja active Pending
- 2001-04-02 SK SK1429-2002A patent/SK287779B6/sk not_active IP Right Cessation
- 2001-04-02 CH CH01917289T patent/CH1272195H1/de unknown
- 2001-04-02 NZ NZ539603A patent/NZ539603A/en not_active IP Right Cessation
- 2001-04-02 DK DK01917289T patent/DK1272195T3/da active
- 2001-04-02 AT AT01917289T patent/ATE306270T1/de active
- 2001-04-02 CA CA002403608A patent/CA2403608A1/en not_active Abandoned
- 2001-04-02 BR BR0109789-0A patent/BR0109789A/pt not_active Application Discontinuation
- 2001-04-02 ES ES01917289T patent/ES2248300T3/es not_active Expired - Lifetime
- 2001-04-02 CN CN01810539A patent/CN1431905A/zh active Pending
- 2001-04-02 DE DE60113975T patent/DE60113975T2/de not_active Expired - Lifetime
- 2001-04-02 EP EP05007561A patent/EP1586323A1/en not_active Withdrawn
-
2002
- 2002-09-19 ZA ZA200207538A patent/ZA200207538B/en unknown
- 2002-09-25 IL IL151932A patent/IL151932A/en unknown
- 2002-10-01 IS IS6576A patent/IS2869B/is unknown
- 2002-10-02 NO NO20024735A patent/NO329949B1/no not_active IP Right Cessation
-
2010
- 2010-09-30 US US12/895,369 patent/US20110183949A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1272195T3 (da) | Anvendelse af fulvestrant til behandling af resistent brystcancer | |
| KR970704430A (ko) | 전립선 질환, 자궁내막증 및 비만증의 치료를 위한 드롤록시펜의 용도(use of droloxifene for the treatment of prostatic diseases endometriosis and obesity) | |
| DE60138611D1 (de) | Synergistische kombinationstherapie zur krebsbehandlung | |
| DK1083889T3 (da) | Tetrahydronaphthalenforbindelser og deres anvendelse til behandling af neurodegenerative sygdomme | |
| DE60138129D1 (de) | Apparat zur behandlung von zähnen | |
| DK1039912T3 (da) | Angiostatiske midler og præparater til behandling af GLC1A-glaukom | |
| DK1382340T3 (da) | Terapeutiske anvendelser af dehydroepiandrosteron til behandling af reduceret libido og osteoporose | |
| DK1446012T3 (da) | Bakteriolytisk kombinationsterapi til behandling af tumorer | |
| EE200100480A (et) | Ksenoon kasutamiseks närvimürgistuste ravis | |
| DK1140181T3 (da) | Konbinationsterapi af bestråling og en COX-2-inhibitor til behandling af neoplasi | |
| IS7137A (is) | Samsett meðferð til meðhöndlunar á krabbameini | |
| DK1716853T3 (da) | Behandling af cancer i menneskekroppen ved anvendelse af ET743 | |
| ATE346614T1 (de) | Vaginale zusammensetzung enthaltend lidocaine zur behandlung von gebärmutterrhythmusstörung | |
| DK1432417T3 (da) | Substituerede imidazolforbindelser og deres anvendelse til behandling af cancer | |
| DE60223576D1 (de) | Hautbehandlungszusammensetzung | |
| MXPA03008582A (es) | Agentes y metodos para tratamiento de cancer. | |
| NO20033123D0 (no) | Terapeutisk hinnedannende sammensetning og behandlingsplan derav | |
| NO20053626L (no) | Blanding omfattende en kombinasjon av en aromataseinhibitor, et progestin og et ostrogen for anvendelse av behandling av endomeriose | |
| DE60221068D1 (de) | Gerät zur tiefenwirksamen Hauttherapie | |
| IS6707A (is) | Efnablanda til forvarna og meðhöndlunar á krabbameini | |
| NO20005548D0 (no) | Mykobakterieinhibitorer | |
| NO20010630D0 (no) | Krummet trapp og trappetrinn for krummet trapp | |
| IS5873A (is) | Meðhöndlun á þunglyndi | |
| IT1314372B1 (it) | Procedimento e dispositivo elettronico per il trattamento dellaceramica per protesi dentale e/o similari. | |
| SI1272195T1 (sl) | Uporaba fulvestranta pri zdravljenju rezistentnega raka dojk |